The tale of two pandemics: Understanding racial and ethnic disparities from the collision of HIV and COVID-19 in the U.S.

两种流行病的故事:从美国 HIV 和 COVID-19 的碰撞中了解种族和民族差异

基本信息

  • 批准号:
    10547314
  • 负责人:
  • 金额:
    $ 72.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-07-08 至 2027-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY The collision of the COVID-19 pandemic with the existing HIV epidemic in the U.S. has exacerbated the decades old racial/ethnic disparities in HIV. For example, Blacks account for 42-44% of HIV diagnoses and deaths among people living with HIV (PLWH) while accounting for only 12% of the population. These racialized disparities in the U.S. HIV epidemic are further compounded by the same disparities emerging in COVID-19. We have shown that PLWH appear to be at higher risk of poorer COVID-19 outcomes than persons not living with HIV (PNLWH), and that the odds of incident COVID-19 infection among PLWH are 60% and 118% higher among Black and Latinx persons, respectively, than whites. These racialized disparities are likely largely driven by social determinants of health (SDoH) underlying our health systems—an understanding of the SDoH pathways that elucidate these disparities is urgently needed to develop the next generation of HIV interventions operating at the structural and social levels, and ever more now in the context of COVID-19. The National COVID Cohort Collaborative (N3C) leverages real-world, national data and presents an unprecedented opportunity to inform the NIH priority aims to understand the social and biologic factors that may affect both HIV and COVID-19 outcomes. N3C is the largest electronic health record (EHR) repository in U.S. history (>10M patients), contains both unparalleled individual-level granular clinical and historical data, and represents the largest U.S. cohort of PLWH with their HIV and COVID-19 outcomes data (>77K), allowing us to evaluate the bi-directional impact of existing HIV infection and COVID-19 outcomes. Furthermore, individual-level data in the N3C are uniquely positioned to merge publicly available datasets that measure area- level SDoH. Our central hypothesis is that the observed racial/ethnic disparities in HIV and COVID-19 occur in a larger context of individuals embedded in social, political, and economic contexts, i.e., SDoH. Understanding these forces, centered on SDoH, allows us to determine the next generation of HIV interventions. Our three aims respond to the NIH call using data science, rigorous machine and statistical learning, and multi-level mediation and epidemic modeling. The goal of Aim 1 (HIV outcomes) is to identify multilevel, social determinants of racial/ethnic disparities in HIV outcomes (e.g., viral suppression [VS] and hospitalization) during the COVID-19 pandemic. The goal of Aim 2 (COVID outcomes) is to understand the independent and aggregated impact of SDoH and clinical characteristics on HIV immune dysfunction for COVID-19 outcomes and vaccine effectiveness (2a) and quantify the differential impact of HIV on COVID-19 outcomes at the U.S. population level by race/ethnicity (2b). The goal of Aim 3 (HIV epidemic modeling) is to quantify the impact of the COVID-19 pandemic on HIV treatment (VS and hospitalization) and prevention (pre-exposure prophylaxis [PrEP] use and HIV/sexually transmitted infections [STI] testing frequency) outcomes by race/ethnicity at the population-level for the national Ending the HIV Epidemic (EHE) initiative’s priority jurisdictions.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rena Chiman Patel其他文献

Rena Chiman Patel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rena Chiman Patel', 18)}}的其他基金

The tale of two pandemics: Understanding racial and ethnic disparities from the collision of HIV and COVID-19 in the U.S.
两种流行病的故事:从美国 HIV 和 COVID-19 的碰撞中了解种族和民族差异
  • 批准号:
    10982807
  • 财政年份:
    2022
  • 资助金额:
    $ 72.23万
  • 项目类别:
The tale of two pandemics: Understanding racial and ethnic disparities from the collision of HIV and COVID-19 in the U.S.
两种流行病的故事:从美国 HIV 和 COVID-19 的碰撞中了解种族和民族差异
  • 批准号:
    10662546
  • 财政年份:
    2022
  • 资助金额:
    $ 72.23万
  • 项目类别:
Co-benefits of co-delivery of long-acting antiretrovirals and contraceptives
长效抗逆转录病毒药物和避孕药联合给药的协同效益
  • 批准号:
    10393063
  • 财政年份:
    2021
  • 资助金额:
    $ 72.23万
  • 项目类别:
Co-benefits of co-delivery of long-acting antiretrovirals and contraceptives
长效抗逆转录病毒药物和避孕药联合给药的协同效益
  • 批准号:
    10253981
  • 财政年份:
    2021
  • 资助金额:
    $ 72.23万
  • 项目类别:
Co-benefits of co-delivery of long-acting antiretrovirals and contraceptives
长效抗逆转录病毒药物和避孕药联合给药的协同效益
  • 批准号:
    10609537
  • 财政年份:
    2021
  • 资助金额:
    $ 72.23万
  • 项目类别:
Using systems science to optimize the impact of point-of-care viral load testing for pediatric HIV management
利用系统科学优化床旁病毒载量检测对儿科艾滋病毒管理的影响
  • 批准号:
    10263333
  • 财政年份:
    2020
  • 资助金额:
    $ 72.23万
  • 项目类别:
Investigating interactions between efavirenz-based antiretroviral therapy and contraceptive implants
研究基于依非韦伦的抗逆转录病毒疗法与植入式避孕药之间的相互作用
  • 批准号:
    9088349
  • 财政年份:
    2015
  • 资助金额:
    $ 72.23万
  • 项目类别:
Investigating interactions between efavirenz-based antiretroviral therapy and contraceptive implants
研究基于依非韦伦的抗逆转录病毒疗法与植入式避孕药之间的相互作用
  • 批准号:
    9178400
  • 财政年份:
    2015
  • 资助金额:
    $ 72.23万
  • 项目类别:
Investigating interactions between efavirenz-based antiretroviral therapy and contraceptive implants
研究基于依非韦伦的抗逆转录病毒疗法与植入式避孕药之间的相互作用
  • 批准号:
    8993281
  • 财政年份:
    2015
  • 资助金额:
    $ 72.23万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 72.23万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.23万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 72.23万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.23万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 72.23万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 72.23万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.23万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 72.23万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 72.23万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.23万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了